Bufotenin

Bufotenin's 5-HT4-mediated cardiac stimulation and peripheral vasoconstriction create significant hemodynamic stress. Individuals with coronary artery disease, heart failure, or structural cardiac abnormalities face elevated risk of acute cardiac events.

Uncontrolled hypertension is an absolute contraindication given bufotenin's documented vasoconstrictive and cardiac stimulant properties. Even controlled hypertension represents elevated risk.

Pre-existing cardiac arrhythmias may be exacerbated by bufotenin's 5-HT4-mediated chronotropic effects, including atrial fibrillation, supraventricular tachycardia, and ventricular arrhythmias.

Personal or family history of psychotic disorders represents a relative contraindication consistent with serotonergic psychedelic class guidance. The transmethylation hypothesis linking endogenous bufotenin to psychosis adds compound-specific concern, though causality is unestablished.

No reproductive or developmental toxicity studies have been conducted. The cardiovascular stress profile and serotonergic activity warrant absolute contraindication during pregnancy and breastfeeding on precautionary grounds.

Concurrent use of any MAO inhibitor (including harmaline, moclobemide, phenelzine, tranylcypromine) is absolutely contraindicated. MAO-A inhibition blocks bufotenin's primary metabolic pathway, potentiating both cardiovascular and serotonergic effects.

Concurrent tramadol use creates risk of serotonin syndrome through complementary serotonergic mechanisms. Tramadol has been implicated in fatal serotonin toxicity when combined with serotonergic agents.